Relonchem Limited Pharmaceutical Import Profile — United Kingdom (DGFT 2022–2026)

Name: Relonchem Limited Pharmaceutical Import Records from India — 4 Products, $5.4M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Relonchem Limited — Pharmaceutical Importer Profile (2026) | 4 Products, $5.4M Trade | TransData Nexus

Relonchem Limited

Pharmaceutical Importer · United Kingdom · Antihistamines & Allergy Focus · $5.4M Total Trade · DGFT Verified

Relonchem Limited is a pharmaceutical importer based in United Kingdom with a total trade value of $5.4M across 4 products in 3 therapeutic categories. Based on 188 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. Relonchem Limited sources from 5 verified Indian suppliers, with Marksans Pharma Limited accounting for 84.2% of imports.

Relonchem Limited — Import Portfolio & Supplier Network

Relonchem Limited import network — 4 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Relonchem Limited?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Marksans Pharma Limited	$5.8M	308	84.2%
Umedica Laboratories Private Limited	$481.3K	19	7.0%
Cadila Pharmaceuticals Limited

What Formulations Does Relonchem Limited Import?

Formulation	Value	Ships
Cetirizine hydrochloride 10 MG tablets	$245.1K	10
Pharmaceutical products-loratadine 10MG	$219.2K	6
Mirtazapine 30 MG tablets 102220 Pack x28=2862160 tabs bach no.	$150.0K	3
Paracetamol 500 MG capsules batch no	$149.0K	8
Pharmaceutical products-sertraline 50 MG	$109.9K	3
Pharmaceutical products-sumatriptan 50	$108.9K	3
Alendronic acid 70MG tablets (r/m : alendronic acid) batch et036e4001 to et036e4004 mfg dt-jan-2024 exp	$108.1K	3
Rosuvastatin 20MG film coated tablets (Box of 2x14 tablets	$97.2K	4
Fluoxetine BP 20 MG	$96.8K	2
Rosuvastatin 20MG film coated tablets Box of 2x14	$96.5K	2
Paracetamol 500 MG capsules batch no	$88.4K	2
Pharmaceutical products-cetirizine	$85.4K	4
Loratadine 10MG tablets batch no	$83.7K	2
Mirtazapine 45 MG tablets (101370 packx28=2838360 tabs) batch no.	$80.9K	3
Mirtazapine 45 MG tablets (100220 packx28=2806160 tabs) batch no.	$80.0K	3

Relonchem Limited imports 217 distinct pharmaceutical formulations. Showing top 15 by value. For full formulation-level data, contact TransData Nexus.

Import Portfolio — Top 4 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Loratadine	Antihistamines & Allergy	$4.0M	124	1.9%	4
2	Nifedipine	Cardiovascular	$597.6K	28	2.0%	10
3	Terbinafine	Antifungals	$417.1K	21	1.5%	14
4	Lisinopril	Cardiovascular	$345.8K	15	0.6%	15

Relonchem Limited imports 4 pharmaceutical products across 3 categories into United Kingdom totaling $5.4M.

Relonchem Limited — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Relonchem Limited, established in 2002, is an independent generic pharmaceutical company headquartered in Widnes, Cheshire, United Kingdom. The company specializes in the importation and distribution of a diverse range of own-label healthcare pharmaceutical products, including anti-diabetic, anti-hypertensive, anti-depressant, anti-cancer, anti-ulcerative, anti-viral, allergy relief, and pain relief medications. With over 400 product licenses, Relonchem Limited plays a significant role in supplying the UK market with essential generic medicines.

The company's registered office is located at Cheshire House, Gorsey Lane, Widnes, Cheshire, England, WA8 0RP. As a private limited company, Relonchem Limited operates independently, focusing on meeting the evolving demands of the global healthcare market. (find-and-update.company-information.service.gov.uk)

2Distribution Network

Relonchem Limited's distribution network is centered in the United Kingdom, with its primary operations based in Widnes, Cheshire. The company maintains state-of-the-art, MHRA-approved manufacturing facilities, enabling the production of various tablets, capsules, and sachets to meet diverse customer needs and regulatory standards. While specific details about additional warehouse locations and logistics capabilities are not publicly disclosed, the company's substantial turnover and extensive product portfolio suggest a well-established distribution infrastructure within the UK.

3Industry Role

In the United Kingdom's pharmaceutical supply chain, Relonchem Limited functions primarily as a wholesaler and distributor of generic pharmaceutical products. By importing and supplying a broad range of own-label medicines, the company ensures the availability of essential generic therapies to meet the healthcare needs of the UK population. This role is crucial in providing cost-effective alternatives to branded medications, thereby enhancing access to necessary treatments.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Relonchem Limited

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Relonchem Limited's sourcing strategy exhibits a high degree of concentration, with a significant portion of its pharmaceutical imports originating from India. Between 2022 and 2026, the company imported finished pharmaceutical formulations valued at $5.4 million USD from India, encompassing 188 shipments and 217 unique formulations. The top five products imported include Loratadine ($4.0 million, 1.9% share), Nifedipine ($598K, 2.0% share), Terbinafine ($417K, 1.5% share), and Lisinopril ($346K, 0.6% share). This concentration indicates a strategic choice to leverage India's robust pharmaceutical manufacturing capabilities, ensuring a consistent supply of high-quality generic medicines.

The shipment data reveals a stable relationship with Indian suppliers, particularly with Marksans Pharma Limited, which accounted for 84.2% of the total import value. This long-term partnership suggests a reliable and efficient supply chain, reducing the risks associated with supplier variability. However, the heavy reliance on a single supplier could pose risks in the event of supply chain disruptions or regulatory changes affecting that supplier.

2Supply Chain Resilience

Relonchem Limited's supply chain resilience is bolstered by its diversified portfolio of 217 unique formulations sourced from five verified Indian suppliers. This diversity mitigates the risks associated with dependency on a single supplier. The company's primary supplier, Marksans Pharma Limited, has demonstrated consistent performance, accounting for 84.2% of the total import value. While this indicates a strong partnership, it also highlights the importance of maintaining robust relationships with backup suppliers to ensure continuity in the event of unforeseen disruptions. Additionally, the company's adherence to stringent quality controls and Good Manufacturing Practice (GMP) standards further enhances the reliability of its supply chain.

Importing Pharmaceuticals into United Kingdom — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for United Kingdom

1Regulatory Authority & Framework

In the United Kingdom, the Medicines and Healthcare products Regulatory Agency (MHRA) is the primary regulatory body overseeing the safety, efficacy, and quality of medicines and medical devices. The MHRA operates under the framework of the Human Medicines Regulations 2012, which transposes European Union directives into UK law. This legislation governs the authorization, manufacture, and distribution of medicinal products within the UK. For Indian pharmaceutical companies, obtaining a marketing authorization from the MHRA is essential for supplying medicines to the UK market.

2Import Licensing & GMP

Import licensing requirements for pharmaceutical products in the UK are stringent. Importers must hold a Wholesale Dealer's License issued by the MHRA, which authorizes the importation and distribution of medicinal products. Additionally, the imported products must comply with Good Manufacturing Practice (GMP) standards. The MHRA recognizes GMP certificates from countries with established regulatory frameworks, including the European Union, World Health Organization (WHO), and the Pharmaceutical Inspection Co-operation Scheme (PIC/S). Indian pharmaceutical manufacturers seeking to export to the UK must ensure their facilities are GMP-compliant and obtain the necessary certifications to facilitate the import process.

Relonchem Limited — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Relonchem Limited's focus on therapeutic areas such as antihistamines and allergy relief (74.7%), cardiovascular (17.5%), and antifungals (7.7%) aligns with prevalent health concerns in the UK. The high import value of Loratadine, a leading antihistamine, indicates strong market demand for allergy relief medications. The inclusion of cardiovascular and antifungal products reflects a strategic approach to address a broad spectrum of health conditions, catering to diverse patient needs.

2Sourcing Profile

Relonchem Limited's sourcing strategy emphasizes generic drug procurement, focusing on finished pharmaceutical formulations rather than active pharmaceutical ingredients (APIs) or bulk drugs. This approach allows the company to offer a wide range of ready-to-use medications, ensuring timely availability for the UK market. India's established pharmaceutical manufacturing sector, with its adherence to international GMP standards, makes it a preferred sourcing destination for Relonchem Limited.

3Market Positioning

Based on its product mix, Relonchem Limited serves the UK market through wholesale distribution channels. By supplying a diverse range of generic pharmaceutical products, the company ensures that healthcare providers have access to affordable and effective treatment options, thereby enhancing patient care across various therapeutic areas.

Seller's Guide — How to Become a Supplier to Relonchem Limited

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to collaborate with Relonchem Limited, particularly in therapeutic areas where the company seeks to expand its portfolio. Identifying gaps in Relonchem Limited's current sourcing, such as emerging therapeutic areas or innovative formulations, can provide avenues for new suppliers to enter the UK market. Establishing partnerships with Relonchem Limited can facilitate access to a well-established distribution network and a broad customer base.

2Requirements & Qualifications

Indian exporters aiming to supply Relonchem Limited and the UK market must ensure their manufacturing facilities comply with international GMP standards recognized by the MHRA. Obtaining a marketing authorization from the MHRA is essential for product registration. Additionally, products must meet UK labeling requirements, including English language labeling and adherence to stability and serialization mandates. Ensuring compliance with these standards is crucial for successful market entry.

3How to Approach

Frequently Asked Questions — Relonchem Limited

What products does Relonchem Limited import from India?

Relonchem Limited imports 4 pharmaceutical products across 3 categories. Top imports: Loratadine ($4.0M), Nifedipine ($597.6K), Terbinafine ($417.1K), Lisinopril ($345.8K).

Who supplies pharmaceuticals to Relonchem Limited from India?

Relonchem Limited sources from 5 verified Indian suppliers. The primary supplier is Marksans Pharma Limited (84.2% of imports, $5.8M).

What is Relonchem Limited's total pharmaceutical import value?

Relonchem Limited's total pharmaceutical import value from India is $5.4M, based on 188 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Relonchem Limited focus on?

Relonchem Limited imports across 3 categories. The largest: Antihistamines & Allergy (74.7%), Cardiovascular (17.5%), Antifungals (7.7%).

Get Full Relonchem Limited Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Profile aggregates 2 company name variants from customs records. For current shipment-level data, contact TransData Nexus.